Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

termittent dosing by both subcutaneous injection and brief (1-2 hour) intravenous (IV) infusion. The maximally tolerable dose (MTD) on a once-per-week for 3 weeks schedule was identified. The follow-on study using the MTD administered on a twice-per- week for 3 weeks schedule has also been completed.

Genta expects to incorporate this new schedule into the ongoing melanoma trial with Abraxane(R) and Temodar(R). These new schedules may ultimately obviate the need for treatment via continuous IV infusion. Abstracts describing results of these studies have been submitted to the 2008 ASCO meeting.

G4544, A New Oral Drug for Skeletal Diseases, Enters Clinical Trials

In late 2007, Genta completed the initial Phase 1 study of G4544, the Company's proprietary small molecule that is intended to treat diseases associated with accelerated bone loss. G4544 contains the active ingredient in Ganite(R), a highly effective drug whose market potential has been constrained by a requirement for continuous IV infusion. No drug-related adverse experience was observed in 30 subjects who received G4544 over a 5- fold dosing range. Further clinical and pharmacokinetic results have been submitted to the 2008 ASCO meeting.

G4544 Development Strategy: The Company has improved the G4544 manufacturing process. Following review and approval of this change, Genta will seek FDA guidance on the 505(b)(2) regulatory pathway, which may shorten development time by allowing use of bioequivalence studies rather than trials to demonstrate efficacy and safety. In this case, Genta owns the NDA for Ganite and has exclusive ownership of important trade secrets, including but not limited to detailed pharmacokinetics and long-term animal toxicology of the active ingredient. The 505(b)(2) approach enables potential approval in the currently approved indication (cancer-related hypercalcemia), in parallel with development in other indications. Low doses of the active ingredient have als
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
(Date:7/25/2014)... CHAPEL HILL, N.C. , July 25, 2014 /PRNewswire/ ... therapeutic area is costly and challenging - as is ... area. Is it possible - or ... products together? If so, where can you combine resources ... remain separated? These are just a ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook to ... Endoscopy Systems market. The report provides value, in millions ... (in US dollars) within market segments: Photo ... Endoscopes , Capsule Endoscopy Data Recorders , ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology:Forces of Change Reshaping Corporate Libraries & Information Services 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5
... FRANCISCO, Jan. 29 Inverseon, Inc.,( http://www.inverseon.com ) ... trial in asthma., In the article by ... 21, (2008), pp. 134-141, entitled, "The safety and,effects ... open-label pilot,study," mild asthmatics were treated for 9 ...
... New Patient Data Posted Online Shows Improvements Across ... The Cystic Fibrosis,Foundation reported today that key indicators ... lung function and nutritional status -- are,rising nationwide ... fact, the outlook for people with CF continues ...
Cached Medicine Technology:Inverseon Announces Positive Phase IIa Asthma Study 2Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes 2
(Date:7/26/2014)... NY (PRWEB) July 26, 2014 As ... magazine on July 23rd, new research by Palo Alto ... to rewrite their playbook, now focusing more on businesses ... masse who have become increasingly wise to their tactics ... founder and CEO/CTO, Joe Caruso, talks about the evolution ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 “Healthy teeth are ... keeping those pearly whites shining,” says Community Health Center of ... Healthy ." , They believe that an integration of medical ... healthy and well. Because of this, they encourage regular cleanings ... with dentist . , “Children and adults will find ...
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... to be filed in U.S. courts, Bernstein Liebhard LLP ... federal health regulators to ban uterine morcellation. According to ... a 46-year-old mother of four from California who was ... cancer called leiomyosarcoma just 10 days after undergoing a ...
(Date:7/26/2014)... Multiple sclerosis (MS), also known ... inflammatory disease in which the insulating covers of ... are damaged. This damage disrupts the ability of ... in a wide range of signs and symptoms, ... sclerosis takes several forms, with new symptoms either ...
Breaking Medicine News(10 mins):Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4
... the journal Clinical Cardiology reveals that a Super Bowl ... in both men and women and in older individuals. , Sports ... the team loses, it can cause some degree of emotional stress. ... Institute, Good Samarian Hospital and Keck School of Medicine at USC ...
... real estate developer Douglas Rosenberg says he has a new ... Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist ... Bredesen, MD has the correct take on how to thwart ... The two have formed a unique partnership aimed at developing ...
... 29 (HealthDay News) -- Dry eye syndrome is common in ... heat, says an eye expert. Symptoms include pain, blurred ... as the eyes try to compensate for the dryness, explains ... and allergies can cause watery eyes, differentiating the two conditions ...
... Randy Dotinga HealthDay Reporter , FRIDAY, Jan. 28 ... percent of patients are considered difficult, and they,re more likely ... of the equation: Researchers also report that older doctors and ... patients. "The patients who have these kinds of problems ...
... that appears to contribute to blood vessel damage in ... Washington University School of Medicine in St. Louis. ... of the nearly 26 million Americans with the disease ... vision loss because of damaged vessels. Reporting in ...
... stress management techniques before prostate cancer surgery may help ... as well as aid in lowering mood disturbance, according ... of Texas MD Anderson Cancer Center. The ... journal Psychosomatic Medicine . It,s the first to ...
Cached Medicine News:Health News:Philanthropist invests $3.5 million in Buck Institute's Alzheimer's drug development effort 2Health News:Philanthropist invests $3.5 million in Buck Institute's Alzheimer's drug development effort 3Health News:Philanthropist invests $3.5 million in Buck Institute's Alzheimer's drug development effort 4Health News:Dry Eye Syndrome Common in Winter 2Health News:Docs Rate Almost 1 in 5 Patients as 'Difficult': Study 2Health News:Researchers discover root cause of blood vessel damage in diabetes 2Health News:Researchers discover root cause of blood vessel damage in diabetes 3Health News:Researchers discover root cause of blood vessel damage in diabetes 4Health News:Pre-surgical stress management boosts immune function, lowers mood disturbance in prostate cancer patients 2Health News:Pre-surgical stress management boosts immune function, lowers mood disturbance in prostate cancer patients 3
... when people are in need of MRI ... the tunnel-type scanners. They have heard of, ... highly claustrophobic and noisy tubes of supercon ... them. What people want is a patient-friendly ...
... spectrofluorometer is the ... among the FLUORAT®-02 ... intended for scientific ... and for operation ...
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
... The BTF-111 miniature ... a user-con?gured spectrometer for ... nm. Con?gurable excitation light ... ?exibility of 2D ?uorescence ...
Medicine Products: